Register & Pay by September 22 to Save Up to $1,400!

Day
Hour
Minute
Second
Confidently Predict LNP Immunogenicity & Safety Profiles to Maximize The Therapeutic Window & Optimize Translatability Into The Clinic

Analyze Your LNP with Precise PKPD, Biodistribution, Immune Response for Applications in GTx Therapy, Vaccination & Beyond

Back for its second iteration, the LNP Immunogenicity & Toxicity Summit will bring together 100+ PKPD, Immunology, Safety, Toxicology experts from biopharma and academia to share best practice and address the next wave of challenges.

Be part of the conversation in 2023, and takeaway:

HW220702 LNP Immunogenicity and Toxicity logo Favicon
HW220702 LNP Immunogenicity and Toxicity logo Favicon
HW220702 LNP Immunogenicity and Toxicity logo Favicon
HW220702 LNP Immunogenicity and Toxicity logo Favicon
HW220702 LNP Immunogenicity and Toxicity logo Favicon
HW220702 LNP Immunogenicity and Toxicity logo Favicon

Robust analysis of LNPs to unpick driving factors behind immune response and immune cell engagement

Preclinical models from in vitro, animal models and 3D tissue models to optimize translatability into the clinic

Understanding of LNP immunogenicity and toxicity read-outs in relation to application of vaccine, gene therapy and chronic disease

Advanced immunogenicity models to minimize anti-PEG response, and PEG alternatives to minimize adverse effects

Widened therapeutic windows and well understood dose limiting toxicities for maximal efficacious benefit

Evaluation of the LNP-payload complex beyond mRNA for next-generation development

In collaboration with Pfizer, BioNTech, Sanofi and Bayer, this 3-day summit will unite senior leaders dedicated to understanding and predicting the next wave of LNP’s immunogenicity and toxicity challenges, to support drug developers to ensure smooth filing with long-term patient safety in mind.

home quote 32202

World-Class Speaker Faculty Includes:

Amy Rosenberg

Senior Director Immunology

Epivax

Hicham Alaoui

Chief Scientific Officer

Glycomine

Jan Diekmann

Senior Director Non-clinical Safety

BioNTech

Joanna Grudzinska

Drug Metabolism & Pharmacokinetics Project Manager

Bayer AG

Maria-Dolores Vazquez-Abad

Medicine Team Lead Clinical Immunogenicity

Pfizer

Olga Lihoradova

Distinguished Scientist

Sanofi

Sophie Tourdot

Immunogenicity Sciences Lead

Pfizer

Virna Cortez-Retamozo

Head Of Group Onco-Pharmacology

Genzyme

LNP Development Community:

Other Events in the Series: